Respiratory failure & ventilation
Dexamethasone doses in patients with COVID‐19 and hypoxia: A systematic review and meta‐analysis
Pooled result · MortalityResult — go to the resultRelative risk 0.97 95% CI 0.79–1.19Authors' conclusion
Based on low to moderate certainty evidence, higher versus standard doses of dexamethasone probably result in little to no difference in mortality, SAEs/SARs, and days alive without renal replacement therapy, but probably increase the number of days alive without invasive mechanical ventilation and circulatory support.
Study context
- Population
- Adults with COVID-19 and hypoxia
- Participants
- 2,478 adults · 8 RCTs
- Comparison
- Higher vs standard doses of dexamethasone
- Outcome
- Mortality
- Follow-up
- 1 month
Methodological detailstrial sequential analysis, Grading of Recommendations Assessment, Development and Evaluation (GRADE), 4 trials (1293 participants) at low risk of bias
- Trial sequential analysis
- GRADE
- 4 trials (1293 participants) at low risk of bias
Pooled result
As reported in the abstract
Relative risk
0.97
95% CI 0.79–1.19
Higher doses vs Standard doses
RR 0.97 (95% CI 0.79–1.19)
Further pooled results
| Outcome | RR (95% CI) | |
|---|---|---|
| Mortality closest to Day 90 | 1.01 (0.86–1.20) | |
| 0.512Relative risk (log scale) |
Days alive without invasive mechanical ventilation and circulatory support
- Higher doses probably increased the number of days alive without invasive mechanical ventilation and circulatory support
Days alive without RRT
- No effect of higher doses
Safety
| Outcome | RR (95% CI) | |
|---|---|---|
| Serious adverse events/reactions (SAEs/SARs) | 1.00 (0.97–1.02) | |
| 0.512Relative risk (log scale) |
Original publication
Dexamethasone doses in patients with COVID‐19 and hypoxia: A systematic review and meta‐analysis. Acta Anaesthesiol Scand. Published 26 October 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →